Kalamazoo, Michigan -- Biotechnology company Armune BioScience has secured $5.55 million in new equity venture capital funding, according to an amended SEC regulatory filing.
Armune is developing molecular diagnostic and prognostic tests for prostate, lung and breast cancers.
The tests promise to enable physicians to make more personalized treatment decisions.
Investors in the financing were not disclosed, nor was how the company intends to use the funding proceeds.
A total of 46 investors have invested in the current round of financing as amended.
Armune is still seeking $369,000 in additional equity investment, according to the filing.